Abstract
As the number of immunotherapies increases, so does the need for biomarkers that can aid in identifying an optimal therapy or combination therapy for patients. These predictive biomarkers are of enormous value to patients but present unique challenges to researchers due to the complexity of the immune system and the variability of individual patient molecular profiles. This chapter draws on recent examples of the use of biomarkers to explore the range of phenotypes encountered in immunotherapy trials for the treatment of neoplastic disease. These examples are discussed in the context of immunoproteomic analysis with a particular focus on the unique challenges that are presented when a high dimensionality technique such as immunoproteomics is applied to study a complex system, the immune system in this case. In order to overcome these challenges, immunoproteomic researchers must pay close attention to study design in order to ensure that the results are not only statistically valid but also that the biomarker strategy as a whole is compatible with the standard of care. We propose that, in spite of its limitations, the use of immunoproteomic analysis of liquid biopsies may present a unique opportunity for translation of immunoproteomic biomarkers to the clinic.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
McShane LM, Altman DG, Sauerbrei W et al (2006) Reporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100:229–235
Altman DG, McShane LM, Sauerbrei W, Taube SE (2012) Reporting recommendations for tumor MARKer prognostic studies (REMARK): explanation and elaboration. PLoS Med 9:e1001216
Pagès F, Mlecnik B, Marliot F et al (2018) International validation of the consensus immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet 391:2128–2139
Galon J, Costes A, Sanchez-Cabo F et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960–1964
Falconi A, Lopes G, Parker JL (2014) Biomarkers and receptor targeted therapies reduce clinical trial risk in non–small-cell lung cancer. J Thorac Oncol 9:163–169
Rizvi NA, Garon EB, Leighl N et al (2015) Optimizing PD-L1 as a biomarker of response with pembrolizumab (pembro; MK-3475) as first-line therapy for PD-L1–positive metastatic non-small cell lung cancer (NSCLC): Updated data from KEYNOTE-001. J Clin Oncol 33(suppl)
Roach C, Zhang N, Corigliano E et al (2016) Development of a companion diagnostic PD-L1 immunohistochemistry assay for Pembrolizumab therapy in non-small-cell lung cancer. Appl Immunohistochem Mol Morphol 24:392–397
Hirsch FR, McElhinny A, Stanforth D et al (2017) PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol 12:208–222
Garon EB, Rizvi NA, Hui R et al (2015) Pembrolizumab for the treatment of non–small-cell lung cancer. N Engl J Med 372:2018–2028
USFDA. (2018) Center for Drug Evaluation, Research Drug Safety and Availability - FDA alerts health care professionals and oncology clinical investigators about an efficacy issue identified in clinical trials for some patients taking Keytruda (pembrolizumab) or Tecentriq (atezolizumab) as monotherapy to treat urothelial cancer with low expression of PD-L1. https://www.fda.gov/drugs/drug-safety-and-availability/fda-alerts-health-care-professionals-and-oncology-clinical-investigators-about-efficacy-issue. Accessed 05/22/2019
Morales-Betanzos CA et al (2017) Quantitative mass spectrometry analysis of PD-L1 protein expression, N-glycosylation and expression stoichiometry with PD-1 and PD-L2 in human melanoma. Mol Cell Proteomics 2017 16(10):1705–1717
Lee HT, Lee JY, Lim H et al (2017) Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. Sci Rep 7:5532
Chevrier S, Levine JH, Zanotelli VRT et al (2017) An immune atlas of clear cell renal cell carcinoma. Cell 169 e18:736–749
Mausner JS, Kramer S (1985) Analytic studies. Mausner & Bahn epidemiology-an introductory text, 2nd edn. WB Saunders, Philadelphia, pp 154–194
Halsey LG, Curran-Everett D, Vowler SL, Drummond GB (2015) The fickle P value generates irreproducible results. Nat Methods 12:179–185
Shachar SS, Mashiach T, Fried G et al (2017) Biopsy of breast cancer metastases: patient characteristics and survival. BMC Cancer 17:7
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Pinto, D.M. (2019). Immunoproteomic Biomarkers: From Publication to Personalized Medicine. In: Fulton, K., Twine, S. (eds) Immunoproteomics. Methods in Molecular Biology, vol 2024. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-9597-4_25
Download citation
DOI: https://doi.org/10.1007/978-1-4939-9597-4_25
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-4939-9596-7
Online ISBN: 978-1-4939-9597-4
eBook Packages: Springer Protocols